投行Piper Sandler首次覆盖生物技术公司First Tracks Biotherapeutics,给予"增持"评级,并设定54美元的目标股价。
该评级反映出分析师对该公司研发管线前景的乐观预期。目标价的设定基于对其创新疗法的估值评估。
投行Piper Sandler首次覆盖生物技术公司First Tracks Biotherapeutics,给予"增持"评级,并设定54美元的目标股价。
该评级反映出分析师对该公司研发管线前景的乐观预期。目标价的设定基于对其创新疗法的估值评估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.